Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Am J Physiol Heart Circ Physiol ; 317(2): H234-H242, 2019 08 01.
Artigo em Inglês | MEDLINE | ID: mdl-31125285

RESUMO

Systemic lupus erythematosus (SLE) is an autoimmune disease that disproportionately affects women of reproductive age and increases their risk for developing hypertension, vascular, and renal disease. Relaxin has potential beneficial therapeutic effects in cardiovascular disease through direct actions on the vasculature. The potential therapeutic benefit of relaxin on SLE-associated cardiovascular and renal risk factors like hypertension has not previously been tested. We hypothesized that relaxin would attenuate hypertension, renal injury, and vascular dysfunction in an established female mouse model of SLE (NZBWF1 mice). Serelaxin (human recombinant relaxin-2, 0.5 mg·kg-1·day-1) or vehicle was administered via osmotic mini-pump for 4 wk in female control (NZW) or SLE mice between 28 and 31 wk of age. Serelaxin treatment increased uterine weights in both groups, suggesting that the Serelaxin was bioactive. Mean arterial pressure, measured by carotid artery catheter, was significantly increased in vehicle-treated SLE mice compared with vehicle-treated controls, but was not changed by Serelaxin treatment. Albumin excretion rate, measured by ELISA, was similar between vehicle- and Serelaxin-treated SLE mice and between vehicle- and Serelaxin-treated control mice. Wire myography was performed using isolated carotid arteries to assess endothelial-independent and -dependent vasodilation, and data confirm that SLE mice have impaired endothelium-independent and -dependent relaxation compared with control mice. Serelaxin treatment did not affect endothelium-independent vasodilation, but exacerbated the endothelium-dependent dysfunction. These data suggest that, contrary to our hypothesis, Serelaxin infusion does not attenuate hypertension, renal injury, or vascular dysfunction in SLE, but worsens underlying vascular endothelial dysfunction in this experimental model of SLE. These data do not support the use of human recombinant relaxin-2 as an antihypertensive in the SLE patient population. NEW & NOTEWORTHY Relaxin is a peptide hormone commonly known for its role in pregnancy and for its use in recent clinical trials for the treatment of heart failure. Evidence suggests that relaxin has immunomodulatory effects; however, the potential therapeutic impact of relaxin in chronic immune mediated disease is unclear. This study tests whether recombinant human relaxin (Serelaxin) attenuates the progression of autoimmunity, and the associated cardiovascular consequences, in an experimental model of systemic lupus erythematosus.


Assuntos
Albuminúria/etiologia , Pressão Arterial/efeitos dos fármacos , Artérias Carótidas/efeitos dos fármacos , Hipertensão/etiologia , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Nefrite Lúpica/etiologia , Relaxina/toxicidade , Vasodilatação/efeitos dos fármacos , Albuminúria/fisiopatologia , Animais , Anticorpos Antinucleares/sangue , Artérias Carótidas/fisiopatologia , Modelos Animais de Doenças , Feminino , Hipertensão/fisiopatologia , Lúpus Eritematoso Sistêmico/complicações , Lúpus Eritematoso Sistêmico/imunologia , Nefrite Lúpica/fisiopatologia , Camundongos Endogâmicos NZB , Proteínas Recombinantes/toxicidade
2.
Physiol Rep ; 7(10): e14059, 2019 05.
Artigo em Inglês | MEDLINE | ID: mdl-31124322

RESUMO

Cardiovascular disease is the major cause of mortality among patients with the autoimmune disorder systemic lupus erythematosus (SLE). Our laboratory previously reported that immunosuppression with mycophenolate mofetil, a common therapy in patients with SLE, attenuates the development of hypertension in an experimental model of SLE. Cyclophosphamide (CYC) is another common therapy for patients with SLE that has contributed to improved disease management; however, its impact on the development of hypertension associated with SLE is not clear. We tested whether treatment with CYC (25 mg/kg, once/week, IP injection) for 4 weeks would attenuate hypertension in an established female mouse model of SLE with hypertension (30-week-old NZBWF1 females). Plasma anti-dsDNA IgG levels, pathogenic for the disease, were lower in CYC-treated SLE mice compared to vehicle-treated SLE mice, suggesting efficacy of the therapy to suppress aberrant immune system function. Mean arterial pressure (MAP) was assessed by carotid artery catheters in conscious mice. Treatment did not attenuate the development of hypertension when compared to vehicle-treated SLE mice; however, urinary albumin excretion was lower in CYC-treated animals. Corresponding with the reduction in autoantibodies, data suggest that CYC treatment lowered circulating CD45R+ B cells. Paradoxically, circulating CD11b+ Ly6G+ neutrophils were increased in CYC-treated SLE mice compared to vehicle treated. Estrus cycling data also suggest that CYC treatment had an impact on ovarian function that may be consistent with reduced circulating estrogen levels. Taken together, these data suggest that CYC treatment attenuates autoantibody production and renal disease during SLE, but that the potential to affect MAP may be blunted by the increase in circulating neutrophils and CYC's impact on ovarian function.


Assuntos
Pressão Arterial/efeitos dos fármacos , Autoimunidade/efeitos dos fármacos , Ciclofosfamida/farmacologia , Hipertensão/prevenção & controle , Imunossupressores/farmacologia , Rim/efeitos dos fármacos , Lúpus Eritematoso Sistêmico/tratamento farmacológico , Nefrite Lúpica/prevenção & controle , Ovário/efeitos dos fármacos , Animais , Anticorpos Antinucleares/sangue , Antígenos Ly/sangue , Linfócitos B/efeitos dos fármacos , Linfócitos B/imunologia , Linfócitos B/metabolismo , Biomarcadores/sangue , Antígeno CD11b/sangue , Modelos Animais de Doenças , Estrogênios/sangue , Estro/efeitos dos fármacos , Feminino , Hipertensão/sangue , Hipertensão/imunologia , Hipertensão/fisiopatologia , Rim/imunologia , Rim/metabolismo , Rim/fisiopatologia , Antígenos Comuns de Leucócito/sangue , Lúpus Eritematoso Sistêmico/sangue , Lúpus Eritematoso Sistêmico/imunologia , Lúpus Eritematoso Sistêmico/fisiopatologia , Nefrite Lúpica/sangue , Nefrite Lúpica/imunologia , Nefrite Lúpica/fisiopatologia , Camundongos Endogâmicos NZB , Neutrófilos/efeitos dos fármacos , Neutrófilos/imunologia , Neutrófilos/metabolismo , Ovário/imunologia , Ovário/metabolismo , Ovário/fisiopatologia
3.
Curr Hypertens Rep ; 21(1): 10, 2019 02 02.
Artigo em Inglês | MEDLINE | ID: mdl-30712132

RESUMO

PURPOSE OF REVIEW: To highlight important new findings on the topic of autoimmune disease-associated hypertension. RECENT FINDINGS: Autoimmune diseases including systemic lupus erythematosus and rheumatoid arthritis are associated with an increased risk for hypertension and cardiovascular disease. A complex interaction among genetic, environmental, hormonal, and metabolic factors contribute to autoimmune disease susceptibility while promoting chronic inflammation that can lead to alterations in blood pressure. Recent studies emphasize an important mechanistic role for autoantibodies in autoimmune disease-associated hypertension. Moving forward, understanding how sex hormones, neutrophils, and mitochondrial dysfunction contribute to hypertension in autoimmune disease will be important. This review examines the prevalent hypertension in autoimmune disease with a focus on the impact of immune system dysfunction on vascular dysfunction and renal hemodynamics as primary mediators with oxidative stress as a main contributor.


Assuntos
Doenças Autoimunes , Hemodinâmica/imunologia , Hipertensão , Doenças Autoimunes/complicações , Doenças Autoimunes/imunologia , Vasos Sanguíneos/imunologia , Vasos Sanguíneos/fisiopatologia , Humanos , Hipertensão/etiologia , Hipertensão/imunologia , Hipertensão/fisiopatologia , Inflamação/fisiopatologia , Rim/irrigação sanguínea , Rim/fisiopatologia
4.
Br J Pharmacol ; 176(12): 1897-1913, 2019 06.
Artigo em Inglês | MEDLINE | ID: mdl-30714094

RESUMO

Patients with autoimmune rheumatic diseases including rheumatoid arthritis and systemic lupus erythematosus have an increased prevalence of hypertension. There is now a large body of evidence showing that the immune system is a key mediator in both human primary hypertension and experimental models. Many of the proposed immunological mechanisms leading to primary hypertension are paralleled in autoimmune rheumatic disorders. Therefore, examining the link between autoimmunity and hypertension can be informative for understanding primary hypertension. This review examines the prevalent hypertension, the immune mediators that contribute to the prevalent hypertension and their impact on renal function and how the risk of hypertension is potentially influenced by common hormonal changes that are associated with autoimmune rheumatic diseases. LINKED ARTICLES: This article is part of a themed section on Immune Targets in Hypertension. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.12/issuetoc.


Assuntos
Doenças Autoimunes/imunologia , Hipertensão/imunologia , Doenças Reumáticas/imunologia , Animais , Autoimunidade/imunologia , Humanos , Hipertensão/prevenção & controle , Sistema Imunitário/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...